



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	79.16
Trade Time:	11:26 AM ET Jun 19, 2018
Change:	1.43 (1.840%)
Day Range	77.14 - 79.49
52-Week Range	74.13 - 147.17
Volume	2,939,543

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup>, ISTODAX<sup>®</sup> and IDHIFA<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Jun 3, 2018*  
[Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel \(JCAR017\) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO](#)
- Jun 3, 2018*  
[Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab \(R<sup>2</sup>\) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018](#)
- Jun 1, 2018*  
[Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting](#)
- Jun 1, 2018*  
[Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVD Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma](#)

*May 31, 2018*  
[Celgene Corporation Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of](#)

## Financials [\[ View all \]](#)

- Feb 7, 2018*  
[Annual Report \(10-K\)](#)
- Apr 30, 2018*  
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2018*  
[Quarterly Report \(10-Q\)](#)
- Oct 26, 2017*  
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)

Peter N. Kellogg to Executive Vice President,  
Chief Corporate Strategy Officer